211 related articles for article (PubMed ID: 8166672)
1. Ras regulatory interactions: novel targets for anti-cancer intervention?
Prendergast GC; Gibbs JB
Bioessays; 1994 Mar; 16(3):187-91. PubMed ID: 8166672
[TBL] [Abstract][Full Text] [Related]
2. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
3. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
4. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
5. Interactions between Ras and Raf: key regulatory proteins in cellular transformation.
Marshall M
Mol Reprod Dev; 1995 Dec; 42(4):493-9. PubMed ID: 8607981
[TBL] [Abstract][Full Text] [Related]
6. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1.
Zhang XF; Settleman J; Kyriakis JM; Takeuchi-Suzuki E; Elledge SJ; Marshall MS; Bruder JT; Rapp UR; Avruch J
Nature; 1993 Jul; 364(6435):308-13. PubMed ID: 8332187
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
[TBL] [Abstract][Full Text] [Related]
8. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
9. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.
Leevers SJ; Paterson HF; Marshall CJ
Nature; 1994 Jun; 369(6479):411-4. PubMed ID: 8196769
[TBL] [Abstract][Full Text] [Related]
10. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
Stang S; Bottorff D; Stone JC
Mol Carcinog; 1996 Jan; 15(1):64-9. PubMed ID: 8561868
[TBL] [Abstract][Full Text] [Related]
11. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro.
Warne PH; Viciana PR; Downward J
Nature; 1993 Jul; 364(6435):352-5. PubMed ID: 8332195
[TBL] [Abstract][Full Text] [Related]
12. Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene.
Li Y; White R
Cancer Res; 1996 Jun; 56(12):2872-6. PubMed ID: 8665528
[TBL] [Abstract][Full Text] [Related]
13. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
Du J; Jiang B; Coffey RJ; Barnard J
Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
[TBL] [Abstract][Full Text] [Related]
14. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.
Cuadrado A; Bruder JT; Heidaran MA; App H; Rapp UR; Aaronson SA
Oncogene; 1993 Sep; 8(9):2443-8. PubMed ID: 8361757
[TBL] [Abstract][Full Text] [Related]
15. Control of ras activation.
Downward J
Cancer Surv; 1996; 27():87-100. PubMed ID: 8909796
[TBL] [Abstract][Full Text] [Related]
16. Opposite role of Ras in tumor necrosis factor-alpha-induced cell cycle regulation: competition for Raf kinase.
Park SJ; Kim YY; Lim JY; Seo GJ; Kim J; Park SI; Park BJ
Biochem Biophys Res Commun; 2001 Oct; 287(5):1140-7. PubMed ID: 11587542
[TBL] [Abstract][Full Text] [Related]
17. Complex formation between the p21ras GTPase-activating protein and phosphoproteins p62 and p190 is independent of p21ras signalling.
Pronk GJ; de Vries-Smits AM; Ellis C; Bos JL
Oncogene; 1993 Oct; 8(10):2773-80. PubMed ID: 8378086
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
19. Novel, activated RAS mutations alter protein-protein interactions.
Dalley BK; Cannon JF
Oncogene; 1996 Sep; 13(6):1209-20. PubMed ID: 8808695
[TBL] [Abstract][Full Text] [Related]
20. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
